RT Journal Article
SR Electronic
T1 100,000 lumens to treat seasonal affective disorder: A proof of concept RCT of bright, whole-room, all-day (BROAD) light therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.29.21265530
DO 10.1101/2021.10.29.21265530
A1 Sandkühler, Julia Fabienne
A1 Brochhagen, Sarah
A1 Muscheidt, Rosa Clara
A1 Grömer, Teja Wolfgang
A1 Müller, Helge
A1 Brauner, Jan Markus
YR 2021
UL http://medrxiv.org/content/early/2021/10/30/2021.10.29.21265530.abstract
AB Background Seasonal affective disorder (SAD) is common and debilitating. The standard of care includes light therapy provided by a light box; however, this treatment is restrictive and only moderately effective. Advances in LED technology enable lighting solutions that emit vastly more light than traditional light boxes. Here, we assess the feasibility of BROAD (Bright, whole-ROom, All-Day) light therapy and get a first estimate for its potential effectiveness.Methods Patients were randomly assigned to a treatment for four weeks; either a very brightly illuminated room in their home for at least six hours per day (BROAD light therapy) or 30 minutes in front of a standard 10,000 lux SAD light box. Feasibility was assessed by monitoring recruitment, adherence, and side effects. SAD symptoms were measured at baseline and after two and four weeks, with the Hamilton Depression Rating Scale-Seasonal Affective Disorders 29-items, self-report version.Results All 62 patients who started treatment were available at four-week follow-up and no significant adverse effects were reported. SAD symptoms of both groups improved similarly and considerably, in line with previous results. Exploratory analyses indicate that a higher illuminance (lux) is associated with a larger symptom improvement in the BROAD light therapy group.Conclusions BROAD light therapy is feasible and seems similarly effective as the standard of care while not confining the participants to 30 minutes in front of a light box. In follow-up trials, BROAD light therapy could be modified for increased illuminance, which would likely improve its effectiveness.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialdrks.de identifier: DRKS00023075Funding StatementFunding was provided by the non-profit organization Centre for Effective Altruism, 2443 Fillmore St., #380-16662, San Francisco, CA 94115, and by one private donor. The trial funders had no role in the design of the study, the collection, analysis or interpretation of data, the writing of the report, or the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the University of Bonn gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://osf.io/ndjm4/. https://osf.io/ndjm4/